FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary ...
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
As of Wednesday, December 17, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 5.19%, which has investors ...
Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.
Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results